PureTech Health (PRTC) noted that its founded entity, Seaport Therapeutics, announced that the first participant has been dosed in the Phase 1 study of GlyphAgo.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTC:
- Buy Rating for PureTech Health Driven by Promising LYT-100 Developments and Strategic Initiatives
- PureTech Health Reports Strong Progress and Financial Stability
- PureTech says Vedanta ulcerative colitis study missed endpoint
- PureTech falls 7% to $16.19 after founded entity study miss
- DiaMedica Therapeutics CMO Lorianne Masuoka resigns, Julie Krop succeeds